Cargando…

Prevalence and associated factors of obesity in inflammatory bowel disease: A case-control study

BACKGROUND: In recent years, an increasing prevalence of obesity in inflammatory bowel disease (IBD) has been observed. Obesity, moreover, has been directly correlated with a more severe clinical course and loss of response to treatment. AIM: To assess the prevalence and associated factors of obesit...

Descripción completa

Detalles Bibliográficos
Autores principales: Losurdo, Giuseppe, La Fortezza, Rosa Federica, Iannone, Andrea, Contaldo, Antonella, Barone, Michele, Ierardi, Enzo, Di Leo, Alfredo, Principi, Mariabeatrice
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7754553/
https://www.ncbi.nlm.nih.gov/pubmed/33384552
http://dx.doi.org/10.3748/wjg.v26.i47.7528
_version_ 1783626221224984576
author Losurdo, Giuseppe
La Fortezza, Rosa Federica
Iannone, Andrea
Contaldo, Antonella
Barone, Michele
Ierardi, Enzo
Di Leo, Alfredo
Principi, Mariabeatrice
author_facet Losurdo, Giuseppe
La Fortezza, Rosa Federica
Iannone, Andrea
Contaldo, Antonella
Barone, Michele
Ierardi, Enzo
Di Leo, Alfredo
Principi, Mariabeatrice
author_sort Losurdo, Giuseppe
collection PubMed
description BACKGROUND: In recent years, an increasing prevalence of obesity in inflammatory bowel disease (IBD) has been observed. Obesity, moreover, has been directly correlated with a more severe clinical course and loss of response to treatment. AIM: To assess the prevalence and associated factors of obesity in IBD. METHODS: We collected data about IBD disease pattern and activity, drugs and laboratory investigations in our center. Anthropometric measures were retrieved and obesity defined as a body mass index (BMI) > 30. Then, we compared characteristics of obese vs non obese patients, and Chi-squared test and Student’s t test were used for discrete and continuous variables, respectively, at univariate analysis. For multivariate analysis, we used binomial logistic regression and estimated odd ratios (OR) and 95% confidence intervals (CI) to ascertain factors associated with obesity. RESULTS: We enrolled 807 patients with IBD, either ulcerative colitis (UC) or Crohn’s disease (CD). Four hundred seventy-four patients were male (58.7%); the average age was 46.2 ± 13.2 years; 438 (54.2%) patients had CD and 369 (45.8%) UC. We enrolled 378 controls, who were comparable to IBD group for age, sex, BMI, obesity, diabetes and abdominal circumference, while more smokers and more subjects with hypertension were observed among controls. The prevalence of obesity was 6.9% in IBD and 7.9% in controls (not statistically different; P = 0.38). In the comparison of obese IBD patients and obese controls, we did not find any difference regarding diabetes and hypertension prevalence, nor in sex or smoking habits. Obese IBD patients were younger than obese controls (51.2  ± 14.9 years vs 60.7 ± 12.1 years, P = 0.03). At univariate analysis, obese IBD were older than normal weight ones (51.2 ± 14.9 vs 44.5 ± 15.8, P = 0.002). IBD onset age was earlier in obese population (44.8 ± 13.6 vs 35.6 ± 15.6, P = 0.004). We did not detect any difference in disease extension. Obese subjects had consumed more frequently long course of systemic steroids (66.6% vs 12.5%, P = 0.02) as well as antibiotics such as metronidazole or ciprofloxacin (71.4% vs 54.7%, P = 0.05). No difference about other drugs (biologics, mesalazine or thiopurines) was observed. Disease activity was similar between obese and non obese subjects both for UC and CD. Obese IBD patients suffered more frequently from arterial hypertension, type 2 diabetes, non-alcoholic fatty liver disease. Regarding laboratory investigations, obese IBD patients had higher levels of triglyceridemia, fasting blood glucose, gamma-glutamyl-transpeptidase. On multivariate analysis, however, the only factor that appeared to be independently linked to obesity in IBD was the high abdominal circumference (OR = 16.3, 95%CI: 1.03-250, P = 0.04). CONCLUSION: Obese IBD patients seem to have features similar to general obese population, and there is no disease-specific factor (disease activity, extension or therapy) that may foster obesity in IBD.
format Online
Article
Text
id pubmed-7754553
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Baishideng Publishing Group Inc
record_format MEDLINE/PubMed
spelling pubmed-77545532020-12-30 Prevalence and associated factors of obesity in inflammatory bowel disease: A case-control study Losurdo, Giuseppe La Fortezza, Rosa Federica Iannone, Andrea Contaldo, Antonella Barone, Michele Ierardi, Enzo Di Leo, Alfredo Principi, Mariabeatrice World J Gastroenterol Case Control Study BACKGROUND: In recent years, an increasing prevalence of obesity in inflammatory bowel disease (IBD) has been observed. Obesity, moreover, has been directly correlated with a more severe clinical course and loss of response to treatment. AIM: To assess the prevalence and associated factors of obesity in IBD. METHODS: We collected data about IBD disease pattern and activity, drugs and laboratory investigations in our center. Anthropometric measures were retrieved and obesity defined as a body mass index (BMI) > 30. Then, we compared characteristics of obese vs non obese patients, and Chi-squared test and Student’s t test were used for discrete and continuous variables, respectively, at univariate analysis. For multivariate analysis, we used binomial logistic regression and estimated odd ratios (OR) and 95% confidence intervals (CI) to ascertain factors associated with obesity. RESULTS: We enrolled 807 patients with IBD, either ulcerative colitis (UC) or Crohn’s disease (CD). Four hundred seventy-four patients were male (58.7%); the average age was 46.2 ± 13.2 years; 438 (54.2%) patients had CD and 369 (45.8%) UC. We enrolled 378 controls, who were comparable to IBD group for age, sex, BMI, obesity, diabetes and abdominal circumference, while more smokers and more subjects with hypertension were observed among controls. The prevalence of obesity was 6.9% in IBD and 7.9% in controls (not statistically different; P = 0.38). In the comparison of obese IBD patients and obese controls, we did not find any difference regarding diabetes and hypertension prevalence, nor in sex or smoking habits. Obese IBD patients were younger than obese controls (51.2  ± 14.9 years vs 60.7 ± 12.1 years, P = 0.03). At univariate analysis, obese IBD were older than normal weight ones (51.2 ± 14.9 vs 44.5 ± 15.8, P = 0.002). IBD onset age was earlier in obese population (44.8 ± 13.6 vs 35.6 ± 15.6, P = 0.004). We did not detect any difference in disease extension. Obese subjects had consumed more frequently long course of systemic steroids (66.6% vs 12.5%, P = 0.02) as well as antibiotics such as metronidazole or ciprofloxacin (71.4% vs 54.7%, P = 0.05). No difference about other drugs (biologics, mesalazine or thiopurines) was observed. Disease activity was similar between obese and non obese subjects both for UC and CD. Obese IBD patients suffered more frequently from arterial hypertension, type 2 diabetes, non-alcoholic fatty liver disease. Regarding laboratory investigations, obese IBD patients had higher levels of triglyceridemia, fasting blood glucose, gamma-glutamyl-transpeptidase. On multivariate analysis, however, the only factor that appeared to be independently linked to obesity in IBD was the high abdominal circumference (OR = 16.3, 95%CI: 1.03-250, P = 0.04). CONCLUSION: Obese IBD patients seem to have features similar to general obese population, and there is no disease-specific factor (disease activity, extension or therapy) that may foster obesity in IBD. Baishideng Publishing Group Inc 2020-12-21 2020-12-21 /pmc/articles/PMC7754553/ /pubmed/33384552 http://dx.doi.org/10.3748/wjg.v26.i47.7528 Text en ©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved. http://creativecommons.org/licenses/by-nc/4.0/ This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
spellingShingle Case Control Study
Losurdo, Giuseppe
La Fortezza, Rosa Federica
Iannone, Andrea
Contaldo, Antonella
Barone, Michele
Ierardi, Enzo
Di Leo, Alfredo
Principi, Mariabeatrice
Prevalence and associated factors of obesity in inflammatory bowel disease: A case-control study
title Prevalence and associated factors of obesity in inflammatory bowel disease: A case-control study
title_full Prevalence and associated factors of obesity in inflammatory bowel disease: A case-control study
title_fullStr Prevalence and associated factors of obesity in inflammatory bowel disease: A case-control study
title_full_unstemmed Prevalence and associated factors of obesity in inflammatory bowel disease: A case-control study
title_short Prevalence and associated factors of obesity in inflammatory bowel disease: A case-control study
title_sort prevalence and associated factors of obesity in inflammatory bowel disease: a case-control study
topic Case Control Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7754553/
https://www.ncbi.nlm.nih.gov/pubmed/33384552
http://dx.doi.org/10.3748/wjg.v26.i47.7528
work_keys_str_mv AT losurdogiuseppe prevalenceandassociatedfactorsofobesityininflammatoryboweldiseaseacasecontrolstudy
AT lafortezzarosafederica prevalenceandassociatedfactorsofobesityininflammatoryboweldiseaseacasecontrolstudy
AT iannoneandrea prevalenceandassociatedfactorsofobesityininflammatoryboweldiseaseacasecontrolstudy
AT contaldoantonella prevalenceandassociatedfactorsofobesityininflammatoryboweldiseaseacasecontrolstudy
AT baronemichele prevalenceandassociatedfactorsofobesityininflammatoryboweldiseaseacasecontrolstudy
AT ierardienzo prevalenceandassociatedfactorsofobesityininflammatoryboweldiseaseacasecontrolstudy
AT dileoalfredo prevalenceandassociatedfactorsofobesityininflammatoryboweldiseaseacasecontrolstudy
AT principimariabeatrice prevalenceandassociatedfactorsofobesityininflammatoryboweldiseaseacasecontrolstudy